Takeda, Samsung Bioepis Partner to Develop Novel Biologic Therapies

03:56 EDT 21 Aug 2017 | Genetic Engineering News

Korean biosimilars firm Samsung Bioepis announced a risk-sharing strategic collaboration with Takeda Pharmaceutical through which the firms will jointly fund and codevelop multiple novel biologic treatments for unmet disease areas. The partners will start work immediately on an initial candidate, TAK-671, for the potential treatment of severe acute pancreatitis. No financial details were disclosed. Samsung Bioepis president and CEO, Christopher Hansung Ko, said the deal marks the start of a new chapter for the firm, which was established in 2012.  “Five years ago, we entered the biopharmaceutical industry with a strong determination to transform the way therapies are brought to patients by replacing legacy processes with new and innovative ones. Together with Takeda, we look forward to realizing this vision by accelerating the development of effective therapies for patients who are currently without a viable treatment option.” “At Takeda, we think differently – and creatively – about ...

Original Article: Takeda, Samsung Bioepis Partner to Develop Novel Biologic Therapies


More From BioPortfolio on "Takeda, Samsung Bioepis Partner to Develop Novel Biologic Therapies"

Quick Search


Relevant Topics

Biotechnology Products
BioPortfolio lists over 550 biotechnology products - please open Direct topic pages: Actos Advair Biopharmaceuticals Biosimilars Biotherapeutics GMO Crops Lipitor ...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...